| Ident. | Authors (with country if any) | Title |
|---|
| 000197 |
Atbin Djamshidian [Royaume-Uni] ; Francisco Cardoso [Brésil] ; Donald Grosset [Royaume-Uni] ; Henrietta Bowden-Jones [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Pathological gambling in Parkinson's disease—a review of the literature |
| 000274 |
S. Sharma [Royaume-Uni] ; R. Bandopadhyay ; T. Lashley ; A. E. M. Renton [Royaume-Uni] ; A. E. Kingsbury ; R. Kumaran ; C. Kallis ; C. Vilari O-Güell ; S. S. O'Sullivan ; Andrew Lees (neurologue) [Royaume-Uni] ; T. Revesz ; N. W. Wood ; J. L. Holton | LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study |
| 000490 |
David A. Gallagher [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? |
| 000549 |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study |
| 000553 |
Atbin Djamshidian [Royaume-Uni, Autriche] ; Ashwani Jha [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni] ; Clare Jacobson [Royaume-Uni] ; Peter Brown [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Bruno B. Averbeck [Royaume-Uni] | Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease |
| 000770 |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward |
| 000920 |
Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni] | Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study |
| 000930 |
Laura Silveira-Moriyama [Royaume-Uni] ; Aviva Petrie [Royaume-Uni] ; David R. Williams [Australie] ; Andrew Evans [Australie] ; Regina Katzenschlager [Autriche] ; Egberto R. Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of a color coded probability scale to interpret smell tests in suspected parkinsonism |
| 000B72 |
Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni] | Adherence to antiparkinson medication in a multicenter European study |
| 000B75 |
Laura Silveira-Moriyama [Royaume-Uni] ; Dharshana Sirisena [Sri Lanka] ; Pasan Gamage [Sri Lanka] ; Ranjanie Gamage [Sri Lanka] ; Rohan De Silva [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka |
| 000C39 |
Laura Silveira-Moriyama [Royaume-Uni] ; Margarete De Jesus Carvalho [Brésil] ; Regina Katzenschlager [Autriche] ; Aviva Petrie [Royaume-Uni] ; Ronald Ranvaud [Brésil] ; Egberto Reis Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil |
| 000F18 |
Andrew Lees (neurologue) [Royaume-Uni] | Unresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthday |
| 000F61 |
Christoph Scherfler [Autriche] ; Johannes Schwarz [Allemagne] ; Angelo Antonini [Italie] ; Donald Grosset [Royaume-Uni] ; Francesc Valldeoriola [Espagne] ; Kenneth Marek [États-Unis] ; Wolfgang Oertel [Allemagne] ; Eduardo Tolosa [Espagne] ; Andrew Lees (neurologue) [Royaume-Uni] ; Werner Poewe [Autriche] | Role of DAT‐SPECT in the diagnostic work up of Parkinsonism |
| 000F90 |
David A. Gallagher [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series |
| 001075 |
Bruno Dubois [France] ; David Burn [Royaume-Uni] ; Christopher Goetz [États-Unis] ; Dag Aarsland [Norvège] ; Richard G. Brown [Royaume-Uni] ; Gerald A. Broe [Australie] ; Dennis Dickson [États-Unis] ; Charles Duyckaerts [France] ; Jefferey Cummings [États-Unis] ; Serge Gauthier [Canada] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Yoshikuni Mizuno [Japon] ; Ian G. Mckeith [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Murat Emre [Turquie] | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force |
| 001098 |
Murat Emre [Turquie] ; Dag Aarsland [Norvège] ; Richard Brown [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Charles Duyckaerts [France] ; Yoshikino Mizuno [Japon] ; Gerald Anthony Broe [Australie] ; Jeffrey Cummings [États-Unis] ; Dennis W. Dickson [États-Unis] ; Serge Gauthier [Canada] ; Jennifer Goldman [États-Unis] ; Christopher Goetz [États-Unis] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Ian Mckeith [Royaume-Uni] ; Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; Christina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Bruno Dubois [France] | Clinical diagnostic criteria for dementia associated with Parkinson's disease |
| 001317 |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study |
| 001396 |
Katherine Grosset [Royaume-Uni] ; Donald Grosset [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Trial of subtherapeutic pergolide in de novo Parkinson's disease |
| 001509 |
Philippe Remy [France] ; Miroslava Doder [France] ; Andrew Lees (neurologue) [Royaume-Uni, France] ; Nora Turjanski [France] ; David Brooks [France] | Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system |
| 001516 |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges |
| 001579 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 001936 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients |
